A home infliximab infusion program

Journal of Pediatric Gastroenterology and Nutrition

Volumn 40, Issue 1, 2005, Pages 67-69

  Condino, Adria A ^a   Fidanza, Sara ^a   Hoffenberg, Edward J ^a,b  

^a CHILDREN S HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Inflammatory Bowel Disease; Infliximab; Pediatrics

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; COLITIS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG COST; DRUG INFUSION; DRUG SAFETY; ENTERITIS; FEMALE; FISTULA; HEART PALPITATION; HOME CARE; HOSPITAL CARE; HUMAN; HYPEREMIA; LIMB PAIN; MALE; PATIENT SATISFACTION; PEDIATRICS; PRIORITY JOURNAL; REMISSION; RESPIRATORY TRACT DISEASE; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; COST-BENEFIT ANALYSIS; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; HOME CARE SERVICES; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, PARENTERAL; MALE; PATIENT SATISFACTION; RETROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME;

EID: 13144303525     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200501000-00012     Document Type: Article

References (11)

1. Navarro F, Hannauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol 2003;98:S18-S23.
2. Podolsky D. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
3. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002;97:2962-72.
4. Kaye M, Wyllie R. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD. Am J Gastroenterol 2003;98(4):717-20.
5. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
6. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-11.
7. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
8. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24.
9. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002;97:1408-14.
10. Friesen CA, Calabro C, Christenson K, et al. Safety of Infliximab Treatment in Pediatric Patients with Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2004;39:265-9.
11. Columbel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.